MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies_Pain
Egalet Corporation (NASDAQ:EGLT)
Organization & Developments: Egalet
Parents
Egalet Corporation (NASDAQ:EGLT)
Children
* The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation.
*The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions
*The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting.
2016: Egalet: FDA Approval Boost On The Way? - Egalet Ltd. (NASDAQ:EGLT)
2017: 2 Small Biopharma CEOs That Should Be Sacked_Egalet
2017: Biotech Forum Daily Digest: Some Recent Positives For Egalet
2017: Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO® ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain
2017: Egalet: Is There A Bottom In Sight? - Egalet Ltd. (NASDAQ:EGLT)
2017: Egalet's abuse-deterrent extended-release oxycodone successful in late-stage back pain study; shares ahead 9% premarket - Egalet Ltd. (NASDAQ:EGLT)
2017: Egalet's abuse-deterrent oxycodone safe in long-term study; shares up 81%_seekingalpha
2018: EGALET CORPORATION bankruptcy case
2018: Egalet down 44% on termination of debt tender offer and default_seekingalpha.com
2018: EGLT: EGALET 2Q:2018 RESULTS_Zacks Small Cap Research
2018: VA_65--Egalet US, Inc. VA Contract No. 36F79718D0556 Effective 9/1/2018 thru 8/31/2023
Jumps
*Key People: Eglet
Finance & Acquisition: Eglet